Medical Communications

Roche’s multiple sclerosis drug, Ocrevus (ocrelizumab), has been a big new growth driver for the company, especially in the US, …

Bad news for Johnson & Johnson as it emerges that the US pharma giant has been ordered to pay out …

Takeda’s surprise announcement, just last week, that it was weighing up a move for Shire had some analysts sceptical about …

Norwegian biopharmaceutical firm Nordic Nanovector has revealed that its Chief Executive Officer Luigi Costa is set to step down from …

Fred van Goor, Principle Research Fellow at Vertex Pharmaceuticals, discusses his history of work in cystic fibrosis and how the …

New figures show that hospital admissions related to obesity have doubled over the last four years in the UK, placing …

28 years after the US first pioneered proton beam therapy at Loma Linda University Medical Center, the UK now has …

Ingrid Copperman recounts the many ways she has dealt with her diagnosis, as well as how the power of social …

NHS England is trialling centres that should be able to provide rapid answers as to whether a patient has cancer …

Celgene has had a rough six months, its share price since the beginning of October has dropped from $146 to …

As we approach the Easter weekend, we at Pharmafocus hope all of our readers have a great long weekend, if …

After the news broke earlier in the week of a group of nearly 100 MPs calling for a parliamentary commission …

On behalf of the Brexit Health Alliance, Sarah Collen, Senior Policy Manager at NHS Confederation, details the potential negative fallout …

As we finally pass into Spring after what still feels like a particularly stubborn Winter, we are pleased to announce …

There are good reasons to think exiting the EU represents a major opportunity for this dynamic and world-leading industry, argues …